OTC Zantac Recall: Sanofi Heeds To Potential Ranitidine Contaminant
Firm opts for recall "as a precautionary measure due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products." Other firms marketing ranitidine in US have started recalls due to concerns about NDMA since potential problem became known in September.
You may also be interested in...
With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.
Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.
FDA advising consumers to choose other heartburn OTCs but isn't ordering ranitidine off market. Consumers concerned about Johnson's Baby Powder due to potential asbestos can choose not only from other brands, but also from Johnson's in containers other than 22-ounce option on recall.